对 Epstein-Barr 病毒的快速抗体反应与原发感染严重程度降低相关,Journal of Clinical Virology

当前位置： X-MOL 学术 › J. Clin. Virol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

对 Epstein-Barr 病毒的快速抗体反应与原发感染严重程度降低相关
Journal of Clinical Virology ( IF 4.0 ) Pub Date : 2022-08-17 , DOI: 10.1016/j.jcv.2022.105267
Jennifer M Geris ₁ , Arianna L Stancari ₁ , Madeline R Meirhaeghe ₁ , Sakhi Gautam ₁ , Corinne Cayatte ₂ , David O Schmeling ₁ , Malek F Okour ₃ , Richard C Brundage ₃ , Gregory M Hayes ₂ , Henry H Balfour ₄

Affiliation

背景

我们调查了大学新生中的 Epstein-Barr 病毒 (EBV) 抗体动力学，这些新生在前瞻性研究中发生了实验室记录的原发性 EBV 感染，并将这些动力学与疾病严重程度相关联。

方法

EBV-naïve 参与者定期收集血液，并通过线印迹和酶免疫测定对 EBV 特异性抗体进行血清测试。线印迹分析包含 EBNA-1、p18、p23、BZLF-1、p138 和 p54 抗原；酶免疫测定含有病毒衣壳抗原和EBNA-1。疾病严重程度 (SOI) 分为 0（无症状）至 6（卧床不起）。将最大 SOI 得分为 0-2 的参与者与最大 SOI 得分为 3-6 的参与者进行比较。使用半参数 COX 模型分析第一次抗体反应的时间。

结果

对 38 名大学生在原发性 EBV 感染之前、期间和之后收集的总共 201 份血清进行了检测。较早的抗体反应与较轻的症状相关。这对于后期开发的抗体最为明显。低 SOI 参与者（64 天）中 p18 IgG 发展的中位时间明显早于高 SOI 患者（119 天；P = 0.0003）。）。患有轻度疾病的参与者比患有更严重疾病的参与者更早产生 EBNA-1 抗体（125 天对 >270 天；P = 0.017）。患有轻度疾病的参与者在感染后 12 周内也表现出更快的抗 IgG EA p138 和 p54 抗体损失（分别为P = 0.012 和P = 0.026）。

结论

这些数据表明，对 EBV 的快速抗体反应与原发性 EBV 感染的严重程度降低相关。

"点击查看英文标题和摘要"

Rapid antibody responses to Epstein-Barr virus correlate with reduced severity of primary infection

Background

We investigated Epstein-Barr virus (EBV) antibody kinetics in university freshmen who developed laboratory-documented primary EBV infection during prospective studies and correlated these kinetics with disease severity.

Methods

EBV-naïve participants had blood collected periodically and sera tested for EBV-specific antibodies with line blot and enzyme immunoassays. The line blot assay contained EBNA-1, p18, p23, BZLF-1, p138, and p54 antigens; the enzyme immunoassay contained viral capsid antigen and EBNA-1. Severity of illness (SOI) was graded 0 (asymptomatic) to 6 (bedridden). Participants with maximum SOI scores 0–2 were compared with those whose maximum SOI scores were 3–6. Time to first antibody response was analyzed using the semi-parametric COX model.

Results

A total of 201 sera from 38 college students collected before, during, and after primary EBV infection were tested. Earlier antibody responses correlated with milder symptoms. This was most pronounced for late-developing antibodies. The median time to development of p18 IgG was significantly earlier among low-SOI participants (64 days) than high-SOI patients (119 days; P = 0.0003).). Participants with mild disease developed EBNA-1 antibodies sooner than participants with more severe disease (125 days versus >270 days; P = 0.017). Participants with mild disease also showed more rapid loss of antibodies against IgG EA p138 and p54 ≥12 weeks post-infection (P = 0.012 and P = 0.026, respectively).